Rachel Leheny Buys CALC Shares
CALC CEO Rachel Leheny purchased 186,729 shares at $0.80 per share.
Key Points
- Rachel Leheny, CEO of CALC, bought 186,729 shares on June 25, 2026, at $0.80 each, totaling $149,383.20.
- CALC shares traded near $0.82 on Monday, with recent insider buying activity boosting interest.
- Analysts like Oppenheimer and HC Wainwright maintain a 'buy' rating with targets up to $16.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Rachel Leheny, the Chief Executive Officer of CALC, made a significant purchase of company stock. On June 25, 2026, she acquired 186,729 shares at an average price of $0.80, amounting to a total value of $149,383.20. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at CalciMedica, Inc.
On June 25, 2026, several insiders at CALC were active buyers. Alongside CEO Rachel Leheny, Chief Medical Officer Sudarshan Hebbar purchased 124,486 shares, and Chief Business Officer Eric Roberts acquired 186,729 shares, both at $0.80 per share. Other notable purchases included Robert Wilson, who bought 1,182,621 shares, and Fred Middleton, who added 248,972 shares to his holdings.
Other Institutional Activity in CALC
Institutional investors have also been active with CALC. Jane Street Group, LLC increased its holdings by 159,312 shares, bringing its total to 178,515 shares valued at approximately $96,398, marking an 829.6% increase. Vanguard Capital Management LLC opened a new position with 169,110 shares worth about $91,319. Meanwhile, Renaissance Technologies LLC boosted its stake by 39,775 shares to a total of 128,075 shares, valued at $69,161, reflecting a 45% increase. 180 Wealth Advisors, LLC significantly expanded its holdings by 94,650 shares, reaching a total of 126,500 shares valued at $68,310, a 297.2% increase. Geode Capital Management, LLC added 23,595 shares, bringing its total to 123,382 shares, valued at $66,652, a 23.6% increase.
Analysts Set New Price Targets
On March 5, 2026, Oppenheimer maintained its 'buy' rating on CALC, setting a price target of $10.00. HC Wainwright & Co. reiterated its 'buy' rating with a target of $16.00 on March 4, 2025. Lucid Capital Markets initiated coverage with a 'buy' rating and a $13.00 target on December 19, 2024. The consensus among analysts is a positive outlook, with a strong 'buy' recommendation and an average target price reflecting confidence in CALC's potential.
Bottom Line
Rachel Leheny's recent purchase of CALC shares highlights her confidence in the company's prospects. Insider buying can often signal optimism from those closest to the business. Investors keep a close watch on such transactions, although it's important to remember that insider activity is only one piece of the broader investment puzzle.
Get CalciMedica, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CALC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.